)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Immuneering
Immuneering (IMRX) investor relations material
Immuneering Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 net loss widened to $24.2M from $15.0M YoY as late-stage atebimetinib development, particularly MAPKeeper 301, drove higher R&D spending.
Cash, cash equivalents and marketable securities totaled $166.1M at Sept. 30, 2026; expected runway was revised from 2029 to Q4 2028.
Atebimetinib is in Phase 3 first-line pancreatic cancer and Phase 1/2a advanced solid tumor trials; no product candidates are approved for sale.
Phase 2 atebimetinib plus mGnP follow-up was extended as patients lived longer than projected; updated data for 55 patients is expected in 1H 2027.
Financial highlights
Q3 2026 operating expenses and operating loss were $25.8M vs. $15.4M YoY; net loss was $24.2M vs. $15.0M.
9M 2026 operating expenses and operating loss were $60.1M vs. $45.6M YoY; net loss was $54.9M vs. $44.4M.
Q3 R&D rose 90.7% to $20.7M from $10.9M, primarily due to higher lead-program clinical costs, including $8.5M in higher MAPKeeper 301 costs.
Q3 G&A increased 12.3% to $5.1M from $4.5M; 9M G&A rose 15.1% to $14.7M, mainly from employee-related and stock-based compensation costs.
Q3 basic and diluted loss per share was $0.37 vs. $0.38; 9M loss per share was $0.85 vs. $1.20.
Outlook and guidance
Existing liquidity is expected to fund operations into Q4 2028, versus prior guidance into 2029; the estimate may prove incorrect and additional capital will be needed thereafter.
Runway revision reflects extended Phase 1/2a activity, larger and faster MAPKeeper 301 enrollment, and commercial-readiness costs; R&D and G&A expenses are expected to increase.
MAPKeeper 301 enrollment target rose from 510 to 570 patients and is ahead of schedule; topline data remain planned for mid-2028, with potential acceleration.
Updated Phase 2 atebimetinib plus mGnP data for N=55 is expected in 1H 2027; the extended follow-up reflects longer-than-projected survival.
First patient dosing in the atebimetinib plus cemiplimab (Libtayo) NSCLC trial and additional anti-PD-1 preclinical data are expected in Q4 2026; next-program IND-enabling work is planned for mid-2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immuneering
- Atebimetinib delivers 17.3 months median OS in first-line pancreatic cancer with high tolerability.IMRX
H.C. Wainwright 28th Annual Global Investment Conference - Atebimetinib nearly doubles survival in first-line pancreatic cancer with superior tolerability.IMRX12th Annual Cantor Fitzgerald Global Healthcare Conference
- Pivotal trial for atebimetinib advanced, with strong interim data and cash runway into 2029.IMRXQ2 2026
- Atebimetinib shows strong survival and tolerability in pancreatic cancer, with pivotal phase III underway.IMRX25th Annual Needham Virtual Healthcare Conference
- Atebimetinib nearly doubles 12-month survival in First-Line pancreatic cancer with strong tolerability.IMRXLeerink Global Healthcare Conference 2026
- Director elections and auditor ratification were approved without stockholder questions.IMRXAGM 2026
- Atebimetinib plus mGnP achieved 94% 6-month OS and strong tolerability in pancreatic cancer.IMRXStudy Update
- 40% response and 80% disease control seen with IMM-1-104 combo in early pancreatic cancer trial.IMRXStudy Update
- IMM-1-104 achieved 43% ORR and 86% DCR with strong tolerability in first-line pancreatic cancer.IMRXStudy Result
Next Immuneering earnings date
Q4 20268 Mar, 2027
Immuneering
Next Immuneering earnings date
Q4 20268 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Immuneering Corporation is a clinical-stage oncology company focused on developing novel therapeutics for cancer patients. The company leverages bioinformatics and computational biology to design drugs that cyclically disrupt core oncogenic signaling pathways, such as the MAPK pathway, with the aim of reducing tumor growth while minimizing toxicity. Immuneering’s pipeline includes its lead product candidate, IMM-1-104, a dual-MEK inhibitor in clinical trials targeting cancers caused by mutations in RAS and/or RAF. Another notable candidate is IMM-6-415, also targeting solid tumors. The company emphasizes a disease-agnostic approach, aiming to address cancers with high unmet medical needs through insights derived from its translational bioinformatics platform. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.